Updated - July 2, 2026 4:49 PM EDT
Scribe Therapeutics on Thursday filed paperwork for a proposed initial public offering to list on the Nasdaq exchange. The company is a clinical-stage biotechnology developer focused on engineering in vivo CRISPR-based approaches that it says are intended to extend healthy lifespan by preventing disease and enabling durable therapeutic interventions.
According to the filing, Scribe positions its work as distinct from current genetic medicines that it describes as largely limited to rare disorders. The company states that it is tailoring its engineered technologies for use in conditions that affect large numbers of people. By concentrating on prevalent diseases with substantial unmet need and clinical burden, Scribe says it intends to pursue genetic medicines that are broadly scalable and preventative at the population level.
Scribe identifies cardiovascular and metabolic diseases as its primary areas of focus, with initial programs directed at key drivers of atherosclerotic cardiovascular disease - ASCVD. The filing explains that the company is designing CRISPR-based therapeutic candidates to be well-tolerated, effective, durable, and capable of scaling broadly enough to move care from symptom-driven and chronic management toward prevention at a population scale. Scribe frames this objective as seeking to democratize access to the cardioprotective effects associated with known genetic variants.
The company's lead candidate, STX-1150, leverages ELXR, which Scribe describes as a highly engineered epigenetic silencing technology. STX-1150 is designed to produce persistent and potent reductions in low-density lipoprotein cholesterol - LDL-C - without effecting permanent genetic changes. The filing characterizes STX-1150 as illustrative of Scribe's effort to change practical therapeutic adherence and real-world outcomes for patients within the multibillion-dollar LDL-C lowering landscape.
Scribe reports that it has obtained regulatory clearance from the Australian Therapeutic Goods Administration, or TGA, and has initiated a first-in-human clinical study of STX-1150 in Australia. The trial is planned to enroll up to 64 adult participants who have elevated LDL-C and an increased risk of ASCVD. The company says it anticipates reporting initial trial data, including safety, tolerability, and LDL-C-lowering activity, in the first half of 2027.
Investment banks named in the filing to serve as underwriters for the proposed offering are Leerink Partners, Goldman Sachs, Guggenheim Securities, and Wells Fargo Securities.
This filing places Scribe among clinical-stage biotech companies that are seeking public capital while progressing early human testing of novel genetic medicine platforms. The company frames its work as shifting the treatment paradigm toward prevention and broad population access, and it has chosen Australia as the location for its initial human study following TGA clearance.